Profile
I am a mathematical biologist and a bioinformatics researcher in the pharmaceutical industry. I received my Ph.D. in Life Science from Hokkaido University in March 2025.
Expertise
My expertise is in mathematical modeling and quantitative data analysis. I work on how dynamic systems can be represented, what can be learned from observations, and how assumptions affect the conclusions. My current interests include pharmacometrics and model-informed drug development. In personal technical notes, I apply population PK, PK/PD, exposure–response and tumor-dynamics models to public data and simulations to examine dose and regimen questions.
Mathematical modeling
Dynamical systems and differential equations, with an emphasis on models that capture the essential structure of a problem. I use models to connect mechanisms with observed patterns and to examine competing explanations.
Statistical inference and uncertainty
Parameter estimation, time-series analysis and model evaluation. I focus on what the available data can support, where uncertainty remains, and how conclusions depend on modeling assumptions.
Interactions and causal reasoning
Analysis of interactions in dynamic systems, including CCM (Convergent Cross Mapping). I am interested in distinguishing predictive relationships from causal interpretations and making the assumptions behind each analysis explicit.
Selected analyses
Personal technical notes based only on published data, public datasets and simulation. They are worked examples of model choice, estimation, diagnostics and uncertainty, not reports of clinical or regulatory work.
Population PK and dosing-interval comparison
- Reimplementing a published mosunetuzumab population PK model: step-up dosing exposure and the limits of extrapolating to receptor occupancy and CRS
- How complex does a population PK model need to be for exposure comparison? Measured nimotuzumab PK
- How far can public summary PK data evaluate a change in the tarlatamab dosing interval?
- Can matching average exposure alone set the tarlatamab dosing interval?
- From public T-cell engager evidence to the next experiment